C12N 2760/16271
Demonstrated in vivo effect
C12N2760/16271 (Demonstrated in vivo effect) appears on 59 US grants and 79 published applications in this corpus.
Search patents in C12N- Granted patents
- 59
- Published applications
- 79
- Assignees
- 26
- Inventors
- 110
- Latest grant
- 10 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 2 | 0 |
| 2004 | 0 | 1 |
| 2005 | 1 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 2 |
| 2008 | 0 | 3 |
| 2009 | 2 | 6 |
| 2010 | 0 | 4 |
| 2011 | 1 | 3 |
| 2012 | 1 | 2 |
| 2013 | 5 | 6 |
| 2014 | 3 | 2 |
| 2015 | 7 | 6 |
| 2016 | 6 | 5 |
| 2017 | 2 | 3 |
| 2018 | 4 | 4 |
| 2019 | 5 | 5 |
| 2020 | 3 | 6 |
| 2021 | 1 | 2 |
| 2022 | 7 | 5 |
| 2023 | 2 | 2 |
| 2024 | 3 | 4 |
| 2025 | 3 | 4 |
| 2026 | 1 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for the treatment of viral infections10 Mar 2026US 12,569,565 B2Cidara Therapeutics, Inc.
- Influenza virus-like particle production in plants11 Nov 2025US 12,467,058 B2Aramis Biotechnologies Inc.
- Immunogenic compositions against influenza27 May 2025US 12,311,020 B2FluGen, Inc.
- Influenza virus hemagglutinin proteins and uses thereof25 Feb 2025US 12,233,123 B2Icahn School of Medicine at Mount Sinai
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof16 Jul 2024US 12,037,364 B2Sanofi Pasteur Limited
- Immunogenic compositions against influenza11 Jun 2026US 2026/0158128 A1FluGen, Inc.
- Low-sugar influenza vaccine and methods thereof11 Jun 2026US 2026/0158130 A1
- Mrna encoding influenza virus-like particle8 Jan 2026US 2026/0007735 A1Sanofi Pasteur Limited
- Polypeptide fragments, immunogenic composition against influenza virus, and implementations thereof23 Oct 2025US 2025/0325649 A1Mynvax Private Limited
- Novel influenza antigens11 Sep 2025US 2025/0281595 A1Glaxosmithkline Biologicals SA
Most cited
By later US patents
- Methods and interferon deficient substrates for the propagation of viruses37US 6,852,522 B1Mount Sinai School of Medicine of New York University · 2005
- Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals35US 6,669,943 B1Mount Sinai School of Medicine of New York University · 2003
- Methods and interferon deficient substrates for the propagation of viruses34US 6,573,079 B1Mount Sinai School of Medicine of New York University · 2003
- Methods and interferon deficient substrates for the propagation of viruses33US 7,494,808 B2Mount Sinai School of Medicine of New York University · 2009
- Process for manufacturing vaccines17US 8,329,184 B2Glaxosmithkline Biologicals SA · 2012